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Abstract. This study presents the first successful use of 
a peptidic vector, DOTATOC, labelled with the [3-emit- 
ting radioisotope yttrium-90, for the treatment of a pa- 
tient with somatostatin receptor-positive abdominal me- 
tastases of a neuroendocrine carcinoma of unknown lo- 
calization. Tumour response and symptomatic relief 
were achieved. In addition, the new substance DOTA- 
TOC was labelled with the diagnostic hemical analogue 
indium-111 and studied in three patients with histopath- 
ologically verified neuroendocrine abdominal tumours 
for its diagnostic sensitivity and compared with the com- 
mercially available OctreoScan. In all patients the kid- 
ney-to-tumour ptake ratio (in counts per pixel) was on 
average 1.9-fold lower with IllIn-DOTATOC than with 
OctreoScan. DOTATOC could be a potential new diag- 
nostic and therapeutic agent in the management of neu- 
roendocrine tumours. 
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In t roduct ion  
In recent years the use of the radiolabelled somatostatin 
analogue lllin_DTPA_D_Phe l_Octreotide (OctreoScan; 
DTPA: diethylene-triamine-penta-acetic acid) (Fig. 1) as 
a specific radiopharmaceutical for the in vivo detection 
of somatostatin receptor-positive tumours has been pro- 
mulgated in clinical nuclear medicine, endocrinology 
and oncology [1, 2]. Despite convincing diagnostic re- 
sults, this analogue cannot be used for labelling with a 
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[3-emitter such as yttrium-90 for therapy. Crucial for 
such a radiotracer is the development of a peptide chel- 
ator conjugate which can hold the radiometal with high 
stability in vivo in order to reduce haematopoietic oxici- 
ty due to bone marrow irradiation. Moreover, a hydro- 
philic conjugate with predominant kidney excretion has 
to be prepared. High kidney retention of the peptides and 
antibody fragments - labelled with a metallic radionu- 
clide - appeared to be one of the main obstacles in the 
potential use of small molecules in internal radiotherapy 
[3]. Therefore, we have developed a new chelator so- 
matostatin analogue which can be labelled stably with 
the diagnostic radionuclide 111In and its therapeutic 
chemical analogue 90y. The new diagnostic radiotracer 
was studied in patients for its sensitivity and compared 
with the commercially available OctreoScan. In one pa- 
tient, the somatostatin analogue labelled with the [3-emit- 
ter 90y was tested for radionuclide therapy. 
Part 1 : D iagnost i c  s tud ies  
Materials, patients and methods 
Radiotracer. We developed a new DOTA chelated somatostatin 
analogue, DOTA-D-Phel-Tyr3-Octreotide (DOTATOC; DOTA: 
1,4,7,10-tetraazacyclododecane-N,N',N",N'-tetra-acetic cid) 
(Fig. 1), in a five-step synthetic procedure according to GMP 
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Fig. 1. Structure formulas of DOTATOC and OctreoScan 
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practice. IllIn-DOTATOC was prepared as follows: 8 gg of 
DOTATOC were dissolved in 190 gl 0.4 M sodium acetate buffer 
(pH 5.5) with 7 mg gentisic acid; after the addition of 6 mCi 
I lllnC13 (0.05 M HC1, Mallinckrodt Med., Petten, The Nether- 
lands), the solution was heated at 90°C for 25 min. Quality con- 
trol was obtained with the use of a Sep-Pak C18 cartridge and 
high-performance liquid chromatography (HPLC), resulting in 
highly pure radioligands with preserved receptor binding affinity 
(K D = 2.2+0.5 nM). 
Patients. Three patients with histopathologically verified neuroen- 
docrine abdominal tumours were investigated after intravenous in- 
jection of 5 mCi 1J lin_OctreoScan and, 2 weeks later, 5 mCi 111in_ 
DOTATOC (specific activity: 1 Ci/gmol). Patient 1 (male, aged 46 
years) had a remaining local tumour and peritoneal carcinosis af- 
ter hemicolectomy because of an obstructing carcinoid tumour of 
the terminal ileum with four of five ileocaecal nodular lymph 
node stations being affected with metastases. At the time of ad- 
mission, 5-hydroxy-3-indolacetic acid and chromogranin-B were 
positive. Patient 2 (male, aged 63 years) had a remaining tumour 
of 3x2x2 cm after subtotal splenopancreatectomy because of a 
malignant insulin-producing pancreatic tumour in the corpus with 
an initial diameter of 13 cm. Patient 3 (male, aged 43 years) had 
metastatic spread of a neuroendocrine tumour of unknown origin 
with multiple liver, abdominal nd skeletal metastases (Figs. 2, 3). 
The patient had received two unsuccessful cycles of chemotherapy 
according to the PEI scheme [cisplatin (Ebewe) 20 mg/m 2 i.v. 
days 1-5, etoposide (Vepesid) 75 mg/m 2i.v. days 1-5, ifosfamide 
(Holoxan) 1.2 g/m 2 i.v. days 1-5; PEI: platin-etoposide-ifosfa- 
mid@ In his past, the patient had undergone surgery with a partial 
resection of the left kidney due to a haemorrhagic cyst. Conven- 
tional computer tomography (CT) of the abdomen and thorax on 
the day of admission showed cystic degeneration f the left kid- 
ney, two large liver metastases in the segments II (4.5x4 cm) and 
V (9x7.5 cm) and multiple abdominal metastases. CT did not re- 
veal any intrapulmonary or mediastinal infiltrations. Skeletal scin- 
tigraphy on the day of admission detected multiple bone metastas- 
es in the first, second and fourth lumbar vertebrae, in the third, 
seventh and ninth thoracic vertebrae, in the sacrum, in the third rib 
on the left ventrolateral side and, additionally, in the posterior 
skull (Fig. 2). Neuron-specific enolase was positive (20 gg/1) on 
the day of admission. 
Methods. Planar scintigraphic images were obtained with a large- 
field-of-view gamma camera (Siemens DIACAM), equipped with 
a medium-energy parallel-hole collimator (matrix 64x64, zoom 
1). The pulse height analyser windows were centered over both 
ltlIn photon peaks (172 and 246 keV) with a window width of 
20%. Data from both windows were then added to the acquisition 
frames. For the first 60 min, dynamic images were acquired from 
posterior views of the abdominal region with 240 frames 
(15 s/frame); one image consisted of four summed dynamic 
frames. Static images (5 min/frame) were acquired from anterior 
and posterior views of the abdominal region 1, 3, 4.5, 6, 24 and 
48 h p.i.; in addition, static images from anterior views of the tho- 
racic region and skull were acquired 24 and 48 h p.i. in patient 3. 
One image consisted of one static frame. Between the 4- and 24-h 
imaging and between the 24- and 48-h imaging, all patients were 
treated with Prontolax (I0 mg bisacodylum). Region of interest 
(ROD analysis (in counts/pixel) of the background, kidneys, liver, 
tumour and/or metastases and spleen was obtained over the whole 
acquisition time. Within each patient, the ROI template was cop- 
ied from one time frame to the next for intra-individual standard- 
ization. Each ROI was normalized to the uptake (in counts/pixel) 
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Fig. 2. Skeletal scintigraphy of patient 3 at the time of admission. 
740 MBq 99mTc-dicarboxydiphosphonate (DPD) was adminis- 
tered. Note the bone metastases inthe sacrum, spine, rib and skull 
of the summed time frames over 5 min. All data were stored on a 
Siemens ICON computer system. 
Radioactivity was measured in blood and urine over 48 h. 
Blood samples were obtained after 2, 5, 10, 20 and 40 min and 1, 
2, 3, 6, 24 and 48 h. Urine was collected at 6-h intervals over 48 h. 
The chemical structure of the radioligand in blood and urine was 
determined by HPLC. 
Results 
Radioactivity cleared quickly from the blood. The blood 
clearance curve was fitted by two exponentials (c~, ~3) 
obtaining half-times of ti/2(c~) = 5__+1 min (76% of radio- 
activity) and t~n(~3) = 110_+30 min (24% of radioactivity) 
(Fig. 4). The radiolabelled peptide showed high stability 
in vivo. No breakdown products were observed up to 6 h 
of observation. The radioactivity was mainly excreted 
via the kidney and found intact in the urine within the 
first 4 h (>96% intact, >50% of activity in the urine). 
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Fig. 3. a Scintiscans of patient 3 5,5 h and 48 h after intravenous injection of 200 MBq 11 qn_DTPA_D_PheLOctreotide (OctreoScan). Pre- 
treatment scan:-NiSte the high kidney uptake over the entire investigated time. The left kidney is without function due to cystic degenera- 
tion. b Scintiscarlg:~f patient 3 1-60 rain and 1, 3, 4.5, 6, 24 and 48 h after intravenous injection of 196 MBq of the newly developed sub- 
stance 11 tln_DOT)X2~_Phel_Tyr3_Octreotide (DOTATOC), Pre-treatment scan 2 weeks later than the scan in a. Note the high kidney excre- 
tion within the first-"[2 rain in contrast to the OctreoScan in a 
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Fig. 4. Typical example of the blood clear- 
ance curve of 1111n_DOTATO C (patient l), 
The curve was fitted by two exponentials 
(~, 13) 
t ime (h) p.i. 
Table 1. Uptake ratios 24 h after injection 
Radiotracer patient k/t k/a t/a 
DOTATOC 1 1.10 1.19 1.08 
OctreoScan 2.00 1.28 0.64 
DOTATOC 2 1.33 2.68 2.02 
OctreoScan 2.54 5.80 2.28 
DOTATOC 3 0.37 2.69 7.34 
OctreoScan 0.70 5.11 7.30 
Two metabolites were detected in the urine at later 
times, the main one being [Illln](DOTA-D-Phel). 
In all three patients, lllIn-DOTATOC showed the 
same diagnostic precision as OctreoScan, but superior 
biodistribution and faster blood and background clear- 
ance (Fig. 3). The kidney-to-tumour (k/t) uptake ratio (in 
counts per pixel) was on average 1.9-fold lower with 
11 qn-DOTATOC than with OctreoScan (Table 1). 
k, Kidney; t, tumor; b, background; 1, liver; a, injected activity (in 
MBq)/MBq 
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Part 2: Treatment 
Materials and methods 
Radiotracer. As a therapeutic radionuclide the pure 13-emitter 90y 
was chosen. The labelling protocol was as described for 111In in 
Part 1 with the exception that different amounts of activity 
(25 mCi and 40 mCi, respectively) were used, resulting in a high- 
ly pure and stable radioligand with preserved receptor binding af- 
finity (K D = 2.6_+0.5 nM). 
Patients. Due to the rapid progression of metastatic spread espite 
two courses of chemotherapy and persisting pain in the lower 
back and abdomen in patient 3 (for a detailed escription of the 
patient's status, see Part 1), we decided to treat his patient experi- 
mentally by internal radiotherapy. Before treatment, umour do- 
simetry was assessed. As the limiting factor for therapy was the 
kidney dose, the kidney retention was estimated by the use of a 
kidney phantom according to the patient's anatomical setting. 
Hereby, it was calculated that the kidney would receive a dose of 
20 Gy if approximately 80mCi 90y-DOTATOC were applied (de- 
tailed data on tumour dosimetry are not presented in this short 
communication, but can be provided by the author). Therefore, we 
started fractionated treatment with two small portions each of 
25 mCi 9°Y-DOTATOC and one portion of 40 mCi 90y-DOTATOC 
within 4 months (first treatment session: 21 October 1996; second 
session: 10 December 1996; third session: 3 February 1997). The 
treatment was approved by the Ethical Committee of the Universi- 
ty of Basel. 
Methods. In each 9°y-DOTATOC treatment session, 1 mCi of 
I llIn-DOTATOC was injected simultaneously in order to control 
the DOTATOC binding. Therefore, 1, 4.5, 24 and 48 h p.i. static 
images (5 rain/image) were acquired. In addition, 4 months after 
the last internal radiotherapy a follow-up I IIIn-DOTATOC scan 
was performed according to the protocol described in Part 1. 
Results 
During the 2 months fol lowing the last internal radio- 
therapy session in patient 3, rapid tumour progression 
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was stopped. This was verif ied by the fol low-up l t l In- 
DOTATOC scan, which exhibited no further metastases 
and no growth of the known tumour masses. In addition, 
the tumour-to-background ratio of the metastases did not 
differ from that before treatment (data not presented). 
Furthermore, the only posit ive tumour marker, neuron- 
specific enolase, decreased from 20 btg/1 to <10 btg/1 dur- 
ing this time. The patient's cl inical status revealed a 
clear subjective improvement after therapy; in particular, 
the pain in his lower back and abdomen disappeared. 
Conclusion 
DOTATOC, label led with l l l In,  is not only a possible 
new diagnostic agent but could, given its superior bioki- 
netics and especial ly k idney-to-tumour ptake ratio, re- 
present a new therapeutic alternative for somatostatin re- 
ceptor-posit ive tumours and metastases when label led 
with a [3-emitter l ike 90y. Further studies in humans with 
90y are in progress. 
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